Drug intelligence / Profile preview

GLUCAN II

Development stage
Preclinical
Administration
Oral, Intravenous, Intramuscular, Subcutaneous, Topical
01

Overview

GLUCAN II appears to refer to a specific preparation or formulation of **beta-glucan**, a group of heterogeneous polysaccharides found in the cell walls of cereals (e.g., oats, barley), fungi (e.g., mushrooms, yeast), bacteria, and some types of algae[4][6]. Beta-glucans are biologically active compounds widely recognized as **immunomodulators**, with demonstrated effects on metabolic health, immune function, and disease risk. They act primarily by activating innate immune cells such as macrophages and natural killer cells via pattern recognition receptors, notably Dectin-1 and complement receptor 3 (CR3). Beta-glucans have been studied as dietary supplements and as drugs, with pharmacological effects dependent on their source, structure, and dosing regimen[1][3][4]. Specific data on a formulation named GLUCAN II, with respect to its manufacturer, regulatory approval, or unique indications, are not found in available literature. Unless "GLUCAN II" is a regional or proprietary supplement, it is presumed to be a named variant or branded version of beta-glucan.

Brand names
GLUCAN II
Other names
GLUCAN II
02

Targets

CLEC7A (Dectin-1)αMβ2 (Integrin αMβ2)

Beyond the preview

Go deeper on GLUCAN II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLUCAN II.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call